What is the primary reason for the significant drop in net income for the nine months ended September 30, 2001?

The primary reasons for the significant decline in net income are lower worldwide sales volumes and pricing pressures across most of DuPont's business segments, coupled with substantial restructuring charges incurred during the period. The weakening global economic conditions, particularly in the U.S., have negatively impacted demand and pricing.

What are the implications of the pending sale of DuPont Pharmaceuticals?

The sale of DuPont Pharmaceuticals to Bristol-Myers Squibb for approximately $7,800 million is a major strategic move. It is expected to generate a significant after-tax gain of about $4,000 million, which will bolster the company's financial position. The proceeds are also earmarked to help reduce debt and fund ongoing share repurchase programs.

How have the restructuring charges impacted the company's financial performance?

The company incurred $1,046 million in restructuring charges for the nine months ended September 30, 2001. These charges are related to employee separations, facility shutdowns, and asset write-downs as DuPont realigns its resources and exits certain businesses. These charges have a direct negative impact on net income and operating results for the period.

What is the company's outlook for the fourth quarter of 2001?

DuPont anticipates fourth quarter 2001 earnings per share to be roughly similar to the third quarter. This outlook is shaped by a mix of factors, including expected benefits from lower raw material costs and restructuring savings, offset by potential for lower volumes, continued pricing pressure, and lower earnings from the Pharmaceuticals segment. The company notes significant uncertainty regarding volume and pricing due to ongoing economic deterioration and consumer confidence.

CTA-PB/CTA-PA 10-Q Quarterly Report Q3 FY2001

Summary

E.I. du Pont de Nemours and Company (DuPont) reported a significant decline in net income for the nine months ended September 30, 2001, compared to the same period in 2000. Net income fell from $2,053 million to $424 million, primarily driven by lower sales volumes and pricing pressures across most segments, exacerbated by a weakening U.S. economy and global economic slowdown. The company also incurred substantial restructuring charges in 2001, totaling $1,046 million, impacting results. Despite the financial challenges, DuPont is actively managing its portfolio. A notable event is the pending sale of its DuPont Pharmaceuticals business to Bristol-Myers Squibb for approximately $7,800 million, expected to generate a significant after-tax gain of $4,000 million. The company also continues its share repurchase program and plans to further reduce debt. Management expects fourth quarter 2001 earnings to be similar to the third quarter, with continued focus on cost savings and navigating economic uncertainties.

Key Highlights

1Net income for the nine months ended September 30, 2001, significantly decreased to $424 million from $2,053 million in the prior year period.
2Consolidated sales for the nine months ended September 30, 2001, declined to $19,497 million from $21,952 million in the prior year period.
3The company recorded $1,046 million in restructuring charges year-to-date 2001, primarily for employee separations, facility shutdowns, and asset write-downs.
4DuPont announced the sale of its DuPont Pharmaceuticals business to Bristol-Myers Squibb for $7,800 million, with an estimated after-tax gain of $4,000 million.
5Cash provided by operations decreased substantially to $922 million for the nine months ended September 30, 2001, compared to $3,144 million in the prior year.
6Capital expenditures for property, plant, and equipment decreased to $1,008 million in the first nine months of 2001 from $1,351 million in the same period of 2000.
7The company plans to continue its share repurchase program and anticipates completing it in early 2002, largely funded by proceeds from the Pharmaceuticals sale.

EIDP, Inc. Quarterly Report for Q3 Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions